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ABSTRACT - PURPOSE: The first genomewide association study indicated that variations in the
phosphodiesterase 4D (PDE4D) gene confer risk for ischemic stroke. However, inconsistencies among the
studies designed to replicate the findings indicated the need for further investigation to elucidate the role of the
PDE4 pathway in stroke pathogenesis. Hence, we studied the effect of global inhibition of the PDE4 pathway in
two rat experimental stroke models, using the PDE4 inhibitor rolipram. Further, the specific role of the PDE4D
isoform in ischemic stroke pathogenesis was studied using PDE4D knockout rats in experimental stroke.
METHODS: Rats were subjected to either the ligation or embolic stroke model and treated with rolipram
(3mg/kg; i.p.) prior to the ischemic insult. Similarly, the PDE4D knockout rats were subjected to experimental
stroke using the embolic model. RESULTS: Global inhibition of the PDE4 pathway using rolipram produced
infarcts that were 225% (p<0.01) and 138% (p<0.05) of control in the ligation and embolic models, respectively.
PDE4D knockout rats subjected to embolic stroke showed no change in infarct size compared to wild-type
control. CONCLUSIONS: Despite increase in infarct size after global inhibition of the PDE4 pathway with
rolipram, specific inhibition of the PDE4D isoform had no effect on experimental stroke. These findings support
a role for the PDE4 pathway, independent of the PDE4D isoform, in ischemic stroke pathogenesis.
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
_______________________________________________________________________
Cyclic nucleotide phosphodiesterases (PDEs)
regulate cyclic adenosine monophosphate (cAMP)
and cyclic guanosine monophosphate (cGMP)
signaling by controlling their degradation (9-11).
Among the PDE family, PDE4 specifically controls
intracellular cAMP levels by catalyzing its
hydrolysis (12) and pharmacological manipulation
of the PDE4 pathway has been exploited
therapeutically in experimental stroke (13, 14).
Despite the growing attention on the involvement of
PDE4 and its isoform, PDE4D, in ischemic stroke
risk, only one experimental stroke study has
attempted to assess the role of the PDE4D isoform
in stroke pathogenesis. However, no causal effect
between PDE4D and stroke injury has been
established (15).
The present study was thus undertaken to
elucidate the role of the PDE4 pathway, particularly
the PDE4D isoform, in stroke pathogenesis. We
_________________________________________

INTRODUCTION
Stroke is a multifactorial disorder and growing
evidence suggests that genetic determinants
contribute to stroke risk (1). The results of the first
genome-wide association study indicated that
variations in phosphodiesterase 4D (PDE4D) gene
are associated with increased stroke susceptibility in
an Icelandic population (2). The same study
suggested that inhibition of PDE4D using
small-molecule inhibitors may decrease stroke risk
in
individuals
predisposed
to
PDE4D
polymorphisms (2). Since then, numerous
replication studies in diverse population groups
have been performed to determine the role of the
PDE4D gene in ischemic stroke predisposition.
While studies from India, Pakistan, China, and
Australia have confirmed a similar association
between PDE4D and ischemic stroke risk, other
studies involving different population groups have
failed to confirm an association (3-8). Hence, the
definite role of PDE4D in stroke pathogenesis
remains unresolved.
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anesthetized with 3% isoflurane in a mixture of
30% oxygen and 70% air. Isoflurane level was
reduced to 1.5% for maintenance of anesthesia
throughout surgery. A ligation model of focal
ischemia was performed as previously described
(17) with modifications. Briefly, both right and left
common carotid arteries (CCAs) were isolated and
loose ligatures were placed around each of them.
The middle cerebral artery (MCA) was ligated with
a 10-O ligature at the point proximal to the rhinal
fissure, and interruption of blood flow was verified
visually. MCA was ligated distal to lenticulostriate
arteries. Three to four hours after preparative
surgery, both CCAs were clamped for 1 hour under
brief anesthesia (less than 5 minutes). Similar
duration of anesthesia was used at the end of
ischemia to allow removal of clips on the CCAs.
Rats subjected to the ligation model were used for
infarct analysis as described below. Fisher-344 rats
were used for the ligation model since previous
studies have demonstrated consistent infarct
formation using this rat strain (18).

studied the effects of global inhibition of the PDE4
pathway using the PDE4 inhibitor rolipram in both
a ligation and an embolic experimental stroke
model. To approximate the effects of genetic
alteration of PDE4 pathway on stroke susceptibility,
we gave rolipram prior to (rather than following)
the ischemic insult. Specific role of the PDE4D
isoform in stroke pathogenesis was determined
using PDE4D knockout (KO) rats in an embolic
experimental stroke model. Recently, we have
shown that PDE4/PDE4D regulates brain
microvascular fibrinolysis in vitro (16). In the
present study, we studied the effect of PDE4
pathway inhibition on brain microvascular
fibrinolysis in vivo, using immunofluorescence and
gene expression microarray.
MATERIALS AND METHODS
Animals:
Adult male Fisher-344 rats weighing 200-250
grams and adult male Wistar rats weighing 300-400
grams (Charles River Labs, Hollister, CA) and adult
male PDE4D knockout Fisher-344 rats, 10-12
weeks old, were used. PDE4D knockout rats were
created using DNA transposon insertional
mutagenesis (Transposagen, Lexington, KY). The
Institutional Animal Care and Use Committee at the
University of California at Irvine approved the
animal protocol in accordance with NIH guidelines.

Embolic model:
For the embolic model, male Wistar rats were
initially anesthetized with 3% isoflurane in a
mixture of 30% oxygen and 70% air. Isoflurane
level was reduced to 1.5% for maintenance of
anesthesia throughout surgery. PDE4D knockout
Fisher-344 rats (Transposagen, Lexington, KY)
weighing 250-350 grams were also subjected to
embolic stroke, with wild-type Fisher-344 rats used
as controls. Embolic stroke was induced as
previously described (19). Briefly, femoral arterial
blood from a donor rat was withdrawn into 20cm of
PE-50 tubing and incubated at 37°C for 2 hours and
then incubated at 4°C for 22 hours. The modified
PE-10 tubing with the pre-formed clots was
advanced towards the origin of MCA through
external carotid artery (ECA) and internal carotid
artery (ICA). Blood clots were injected into the ICA
through the carotid catheter with 5µl saline. Since
the embolic stroke model was first established using
the Wistar rats and since then has been widely
performed on Wister rats, we used this specific
strain for embolic stroke in the present study (20).
The Fisher-344 rats were used to study the effect of
the PDE4D isoform on embolic stroke since this is
a readily available knockout rat strain.
Arterial blood gases, blood pressure and inner
ear temperature were measured at the time of
dosing, before surgery, after onset of stroke, and

Drug preparation and administration:
Rolipram (Fisher Scientific, Fairlawn, NJ) was
dissolved in vehicle (2% DMSO in distilled water),
at a concentration of 1 mg/ml. Both drug and
vehicle were pre-dissolved, individually packed,
and kept at -20ºC. Individual containers were coded
by a researcher not involved in other experimental
procedures. Animals were equally divided into
experimental and control groups. Either drug (3
mg/kg) or vehicle was given i.p. to rats 30 minutes
before the onset of ischemia for ligation model and
60 minutes before the onset of ischemia for embolic
model. The time of treatment administration
differed for the two models due to difference in the
time required for surgical preparation and induction
of experimental stroke. Inner ear temperature was
measured at the time of i.p. dosing, after brain
ischemia and reperfusion, and before sacrifice.
Ligation model:
Male Fisher-344

adult

rats

were

initially
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before sacrifice. Arterial blood gases were
measured using Trupoint blood analysis system
(ItcMed, Edison, NJ). Relative regional blood flow
was measured using Laser Doppler flow meter
(Perimed AB, Jarfalla, Sweden). 24 hours after
onset of stroke, examinations were performed as
previously described (19), and animals with score 0
and 1 were excluded. Rats subjected to embolic
stroke were used for infarct analysis or mechanistic
studies as described below.

Western blot and PCR:
Brain endothelial cells obtained from rats subjected
to embolic stroke were used for Western blot and
quantitative real-time polymerase chain reaction as
previously described (23). Antibodies to occludin
(BD Bioscience, San Diego, CA), claudin-5 (BD
Bioscience, San Diego, CA), tPA (Molecular
Innovations, Novi, MI), PAI-1 (Molecular
Innovations, Novi, MI) or actin (Santa Cruz, Santa
Cruz, CA) were used. The primers and probes for
real-time PCR were: tPA Forward: 5’ – CCCTGA
CCCCGACGTACAG-3’, Reverse: 5’ – ATGCTT
GCCGTAGCCAGAA-3’ Probe: FAM – TCCCTGA
CTGGACAGAGTGTGAGC-TAMRA;
β-actin
Forward: 5’-TTCAACACCCCAGCCATGT -3’,
Reverse: 5’-TGGTACGACCAGAGGCATACAG
-3’, Probe: FAM – CGTAGCCATCCAG
GCTGTGTTG -TAMRA. RT2 Profiler PCR array
system (PARN-015A, SABiosciences, Frederick,
MD) profiling 84 genes related to endothelial cell
biology and 6 housekeeping genes were used for
PCR array study. Ct values of each gene were
calculated and imported into PCR Array Data
Analysis Portal (SABiosciences, Frederick, MD).

TTC staining:
Animals were euthanized 24 hours after stroke
onset by exsanguination under isoflurane
anesthesia. The brains were then quickly removed
and sectioned coronally at 2-mm intervals and
incubated in a 1% solution of 2, 3 , 5 – tripheny ltetrazolium chloride (TTC) at 37°C for vital
staining. Areas not stained red with TTC were
considered infarcted. Infarct areas were measured in
each section using image analysis software
(Image-Pro, Media Cybernetics, Inc. Silver Spring,
MD) and the infarct volume calculated by summing
the areas in adjacent sections. Percentage of injury
was calculated as percent of infarct volume to total
volume of contralateral hemisphere.

STATISTICAL ANALYSIS
Means between experimental and control groups
were compared using Student t-tests; differences
among the four temporal profile groups in the
validation study were tested using analysis of
variance with Tukey’s method for pairwise
comparisons. p<0.05 was considered statistically
significant. Data are presented as means ± standard
error.

Immunostaining:
24 hours after embolic stroke, rat brains were
quickly frozen in isopentane pre-chilled with dry
ice. 7 µm thick sections were cut using cryostat and
stained with primary rabbit polyclonal antibodies
against either von Willebrand factor (vWF)
(DAKO. Carpenturia, CA), an endothelial marker,
or tissue plasminogen activator (tPA) (Molecular
innovations, Novi, MI), and then incubated with
FITC-conjugated sheep anti-rabbit immunoglobulin
G (Sigma-Aldrich, St. Louis, MO) for 30 minutes at
room temperature. Sections were analyzed by
fluorescence microscopy.

RESULTS
Global inhibition of the PDE4 pathway using
rolipram:
In preliminary studies we investigated the temporal
profile of the ligation model, with three groups of
eight rats subjected to 30, 60, or 90 minutes of
arterial occlusion, followed by releasing clips on
both the right and left CCA. Three additional
animals were included as sham operation, in which
only the right MCA was permanently ligated, while
the CCAs were only exposed and circled with 4-O
silk suture. No infarction was found in the
sham-operated animals, consistent with prior
observations (24). The proportion of infarct to total
volume increased with increasing minutes of

Cerebral vessel isolation:
24 hours after embolic stroke, cortex from rats
treated with rolipram (3mg/kg) or vehicle (2%
DMSO in distilled water) was isolated.
Homogenized cortex tissues were centrifuged at
1000rpm for 20min. Pellets were suspended 10ml
25% BSA in HBSS and centrifuged at 1000g for
20min. Suspended vessels were put in 1ml
HBSS/5% FBS, and passed through 40µm cell
strainer to isolate brain endothelial cells (21,22).
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significantly in mean infarct volume measured 24
hours after onset of stroke (20±9% vs. 18±6%,
Figure 3B).

ischemia: 1%, 14 % and 26% in the 30, 60 and 90
minute ischemia groups, respectively. The
differences between the 30 and 60 minute ischemia
groups and between the 30 and 90 minute ischemia
groups were statistically significant, and 60 minute
occlusion was chosen for the present study.
In the treatment study using the ligation model,
all 18 vehicle-treated rats survived transient focal
cerebral ischemia, while 3 out of 18
rolipram-treated animals died 8-20 hours after
arterial reperfusion. Brain temperature, measured at
inner ear, was slightly lower (1.8±0.1 °C at the time
of ischemia, p<0.001 and 1.7±0.1 °C at the time of
reperfusion, p<0.001) in rolipram-treated animals
compared to vehicle-treated animals (data not
shown). The mean percentage of hemisphere
infarction in the vehicle-treated animals was
11%±2. Rats subjected to rolipram treatment prior
to the onset of transient focal cerebral ischemia had
a significantly higher infarct volume (25%±3%,
225% of control, p<0.01, Figure 1).
In the treatment study using the embolic
model, body temperature, blood pressure, blood
gas, blood pH and blood flow did not differ after
rolipram treatment and experimental stroke
compared with pretreatment levels, while regional
blood flow decreased significantly (53%±4% of
pretreatment levels, p<0.001) (data not shown). The
mean percentage of cerebral infarction in 16
vehicle-treated animals was 23%±3%. The 16 rats
subjected to rolipram treatment prior to onset of
transient focal cerebral ischemia had significantly
larger infarction (32%±2%, 138% of control,
p<0.05, Figure 2).
Immunostaining studies demonstrated similar
patterns of tPA and fibrin deposition in
rolipram-treated and control rats. No significant
changes in tPA mRNA by real-time PCR and tPA,
PAI-1, claudin-5 or occludin protein by Western
blot following rolipram treatment were seen as
compared with control. PCR endothelial array
analysis of brain vessels of rolipram-treated rats
showed no significant changes compared to control
animals (data not shown).

DISCUSSION
Our results indicate that global inhibition of the
PDE4 pathway with rolipram prior to a stroke insult
increases infarct size in both the ligation and
embolic rat models of experimental stroke, with
increases ranging from 138-225% of control. No
difference in infarct size was observed between
PDE4D knockout and wild-type rats subjected to
the embolic stroke model. Our observed effects of
global PDE4 and specific PDE4D isoform
inhibition thus suggest a role of the PDE4 pathway,
independent of the PDE4D isoform, in stroke
pathogenesis.
Rolipram (4 - [ 3 - (cyclopentyloxy) – 4 – meth
oxyphenyl]-2-pyrrolidinone), one of the most
extensively studied PDE4 inhibitors, enhances the
availability of intracellular cAMP in the brain by
inhibiting its hydrolysis (25). Rolipram has an IC50
of approximately 1 µM and shows at least a
100-fold selectivity for PDE4 family (26). Global
inhibition of the PDE4 pathway with rolipram
treatment in the present study results in increased
infarct size suggesting the involvement of the PDE4
pathway in stroke pathogenesis. This finding agrees
with other reports that have shown that rolipram
treatment exacerbated neuronal injury in
experimental stroke (27-29). In addition to cerebral
ischemia, reports have shown exacerbation of brain
injury by rolipram treatment in other models of
CNS disease (30, 31). One possible mechanism for
exacerbation of brain injury by cAMP-stimulating
agents such as rolipram is induction of
compensatory upregulation of certain PDE4
isoforms (32-34) to accelerate cAMP degradation
(35, 36). Hence, treatment with rolipram prior to
ischemic insult in the present study may have
caused an increase in PDE4 activity resulting in
exacerbation of ischemic infarction. While there is
evidence that inhibition of the PDE4 pathway by
rolipram reduces expression of tPA and enhances
effects of ischemia in vitro (16), we observed no
difference in tPA expression or fibrin deposition in
the rolipram treated group. Note that some studies
have reported beneficial effects of rolipram in
experimental models of stroke (13, 14).
Contradictory effects of global inhibition of the
PDE4 pathway on experimental stroke outcome

Inhibition of PDE4D isoform:
To determine effects of the PDE4D isoforms on
infarct size in experimental stroke, we used 6
PDE4D knockout rats and 6 wild-type controls.
These animals demonstrated no PDE4D expression
by Western blot of cerebral vascular preparation
(Figure 3A). The two groups did not differ
365
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wild-type controls, suggesting that the PDE4D
isoform is unlikely to be involved in stroke
pathogenesis. This is consistent with the conflicting
literature on the role of the PDE4D isoform in
human stroke pathogenesis (3-8). Rolipram on the
other hand is known to inhibit all forms of PDE4
including PDE4A, which is highly expressed on the
brain microvasculature (15), and it is likely that
isoforms other than PDE4D may be involved in
exacerbation of stroke injury observed in the
present study.

may be due to differences in experimental models,
designs and brain regions examined. Extending the
survival time beyond 24 hours may be necessary to
observe protective effects of global inhibition of
PDE4 pathway with rolipram.
A role for PDE4D has been suggested in stroke
pathogenesis and inhibition of the PDE4D isoform
may decrease the risk for stroke in susceptible
individuals (2). However, in the present study loss
of the PDE4D isoform in knock-out rats did not
produce change in infarct size compared to

A

D

B

E

C

F

G

Figure 1. Coronal sections of rat brain stained with TTC 24 hours following onset of focal cerebral ischemia using ligation
model. A, B, C and D, E, F are sections from vehicle (n=18) and rolipram (n=15) treated animal, respectively. (G) Effects
of rolipram treatment on infarct size using ligation model of focal cerebral ischemia. Values are means±SE; **p < 0.01.
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A

C

B

D

E

Figure 2. Coronal sections of rat brain stained with TTC 24 hours following onset of embolic stroke. A, B and C, D are
sections from vehicle (n=16) and rolipram (n=16) treated animal, respectively. (E) Effects of rolipram treatment on infarct
size with embolic experimental stroke model. Values are means±SE; n=16*p < 0.05.

determine the association between modulation of
other PDE4 isoforms and ischemic stroke risk.

In summary, the present study shows that
global inhibition of the PDE4 pathway with
rolipram prior to an ischemic insult exacerbates
tissue injury in two different models of
experimental stroke, supporting a role of the PDE4
pathway in stroke pathogenesis. However, no
evidence supporting a role of the PDE4D isoform in
stroke pathogenesis was found. This suggests
involvement of a different PDE4 isoform in stroke
pathogenesis, and further studies are required to
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A

WT

KO

PDE4D

Β-actin

B

Figure 3. A. Measurement of PDE4D protein levels by Western blot of cerebral vascular preparation. PDE4D knockout
rats (KO) showed no PDE4D expression compared to wild-type rats (WT). B. Infarct size of PDE4D knockout rat (n=6)
compared to wild-type (n=6) control following embolic experimental stroke model. WT: wild-type rats; KO: homozygous
knockout rats. Values are means±SE.
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